BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shiffman ML, James AM, Long AG, Alexander PC. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol. 2015;110:1179-1185. [PMID: 26215530 DOI: 10.1038/ajg.2015.218] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Guarino M, Morisco F, Valvano MR, Ippolito AM, Librandi M, Andriulli N, Greco M, Amoruso A, Iacobellis A, Niro G, Caporaso N, Andriulli A. Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis. Aliment Pharmacol Ther 2017;45:1193-200. [PMID: 28261822 DOI: 10.1111/apt.14017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
2 Nguyen DT, Tran TTT, Nghiem NM, Le PT, Vo QM, Day J, Rahman M, Le HM. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. PLoS One 2020;15:e0233446. [PMID: 32433676 DOI: 10.1371/journal.pone.0233446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 2016;44:400-10. [DOI: 10.1111/apt.13696] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
4 Singh S, Nautiyal A, Loke YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. Frontline Gastroenterol 2018;9:262-70. [PMID: 30245788 DOI: 10.1136/flgastro-2018-101017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
5 Alam I, Brown K, Donovan C, Forlenza J, Lauwers K, Mah'moud MA, Manch R, Mohanty SR, Prabhakar A, Reindollar R, DeMasi R, Slim J, Tandon N, Villadiego S, Naggie S. Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study. Open Forum Infect Dis 2017;4:ofw258. [PMID: 28480251 DOI: 10.1093/ofid/ofw258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, Curry MP, Tsai N, Chaiyakunapruk N, Lee Y, Petersen J, Buggisch P. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 2017;65:1094-103. [PMID: 28027579 DOI: 10.1002/hep.29005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
7 Focaccia R, de Mello R, Montes P, Conti F. Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA). Arch Hepat Res 2015;1:009-17. [DOI: 10.17352/ahr.000003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Kim BY, Nam H, Yoo JJ, Cho YY, Choi DH, Jung CH, Mok JO, Kim CH. Association between alcohol consumption status and obesity-related comorbidities in men: data from the 2016 Korean community health survey. BMC Public Health 2021;21:733. [PMID: 33858402 DOI: 10.1186/s12889-021-10776-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S; ANRS/AFEF HEPATHER study group. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infect Dis 2019;19:300. [PMID: 30940090 DOI: 10.1186/s12879-019-3923-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
11 Weiler N, Zeuzem S, Welker MW. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol 2016; 22(41): 9044-9056 [PMID: 27895394 DOI: 10.3748/wjg.v22.i41.9044] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64:1824-1833. [PMID: 26449729 DOI: 10.1136/gutjnl-2015-310421] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 15.5] [Reference Citation Analysis]
13 Vargas HE. Hepatitis C Treatment in 2016: Reasons to Be an OPTIMIST: Hepatology, Vol. XX, No. X, 2016 Vargas. Hepatology 2016;64:330-2. [DOI: 10.1002/hep.28559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology 2016;64:405-14. [PMID: 27115523 DOI: 10.1002/hep.28625] [Cited by in Crossref: 148] [Cited by in F6Publishing: 140] [Article Influence: 24.7] [Reference Citation Analysis]
15 Lutchman G, Nguyen NH, Chang CY, Ahmed A, Daugherty T, Garcia G, Kumari R, Gupta S, Doshi D, Nguyen MH. Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. Aliment Pharmacol Ther 2016;44:738-46. [PMID: 27506182 DOI: 10.1111/apt.13761] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
16 Kao J, Jensen DM, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng C, Roberts SK, Lee Y, Bhore R, Mendez P, Hughes E, Noviello S. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int 2016;36:954-62. [DOI: 10.1111/liv.13049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
17 Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P. Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort. Hepat Med 2017;9:67-73. [PMID: 29296102 DOI: 10.2147/HMER.S149578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Pillai AA, Wedd J, Norvell JP, Parekh S, Cheng N, Young N, Spivey JR, Ford R. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Am J Gastroenterol. 2016;111:250-260. [PMID: 26832650 DOI: 10.1038/ajg.2015.422] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
19 Maasoumy B, Vermehren J. Diagnostics in hepatitis C: The end of response-guided therapy? J Hepatol 2016;65:S67-81. [PMID: 27641989 DOI: 10.1016/j.jhep.2016.07.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
20 Vutien P, Hoang J, Brooks L Jr, Nguyen NH, Nguyen MH. Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States. Medicine (Baltimore) 2016;95:e3719. [PMID: 27258498 DOI: 10.1097/MD.0000000000003719] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 5.2] [Reference Citation Analysis]
21 Airewele NE, Shiffman ML. Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. Clin Liver Dis 2021;25:817-29. [PMID: 34593155 DOI: 10.1016/j.cld.2021.06.008] [Reference Citation Analysis]
22 Ito J, Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kumagai K, Kikuchi H, Miyagishima T, Kobayashi T, Kimura M, Yamasaki K, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Terashita K, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; for the NORTE Study Group. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection: Naturally occurring NS5B RAVs in HCV-1b. Hepatol Res 2016;46:1294-303. [DOI: 10.1111/hepr.12685] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
23 Welker MW, Zeuzem S. Pre- and Post-Transplant Antiviral Therapy (HBV, HCV). Visc Med 2016;32:105-9. [PMID: 27413727 DOI: 10.1159/000445152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
24 Ikawa-Yoshida A, Matsuo S, Kato A, Ohmori Y, Higashida A, Kaneko E, Matsumoto M. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Int J Exp Pathol 2017;98:221-33. [PMID: 28895242 DOI: 10.1111/iep.12240] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
25 Welker MW, Luhne S, Lange CM, Vermehren J, Farnik H, Herrmann E, Welzel T, Zeuzem S, Sarrazin C. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2016;64:790-799. [PMID: 26658684 DOI: 10.1016/j.jhep.2015.11.034] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
26 Aby E, Jimenez MA, Grotts JF, Agopian V, French SW, Busuttil RW, Saab S. Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C. J Clin Transl Hepatol 2017;5:197-202. [PMID: 28936400 DOI: 10.14218/JCTH.2016.00073] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Maan R, van der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res 2016;5:F1000 Faculty Rev-367. [PMID: 27006761 DOI: 10.12688/f1000research.7399.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
28 Gimeno-Ballester V, Simón MÁ, Trigo C, Mar J, San Miguel R. Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence. Expert Rev Gastroenterol Hepatol 2016;10:1289-303. [PMID: 27626505 DOI: 10.1080/17474124.2016.1236682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]